Role of type I interferon in inducing a protective immune response: Perspectives for clinical applications

Vilcek, 2006, Fifty years of interferon research: aiming at a moving target, Immunity, 25, 343, 10.1016/j.immuni.2006.08.008 Gresser, 2007, The antitumor effects of interferon: a personal history, Biochimie, 89, 723, 10.1016/j.biochi.2007.03.005 Belardelli, 1996, The neglected role of type I interferon in the T-cell response: implications for its clinical use, Immunol Today, 17, 369, 10.1016/0167-5699(96)10027-X Belardelli, 2002, Cytokines as a link between innate and adaptive antitumor immunity, Trends Immunol, 23, 201, 10.1016/S1471-4906(02)02195-6 Rizza, 2011, IFN-alpha as a vaccine adjuvant: recent insights into the mechanisms and perspectives for its clinical use, Expert Rev Vaccines, 10, 487, 10.1586/erv.11.9 Le Bon, 2001, Type I interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo, Immunity, 14, 461, 10.1016/S1074-7613(01)00126-1 Santini, 2000, Type I interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-PBL-SCID mice, J Exp Med, 191, 1777, 10.1084/jem.191.10.1777 Affabris, 1982, Isolation of interferon-resistant variants of Friend erythroleukemia cells: effects of interferon and ouabain, Virology, 120, 441, 10.1016/0042-6822(82)90044-7 Gresser, 1991, Host humoral and cellular immune mechanisms in the continued suppression of Friend erythroleukemia metastases after interferon alpha/beta treatment in mice, J Exp Med, 173, 1193, 10.1084/jem.173.5.1193 Ferrantini, 2000, Gene therapy of cancer with interferon: lessons from tumor models and perspectives for clinical applications, Sem Cancer Biol, 10, 145, 10.1006/scbi.2000.0333 Ferrantini, 1993, Alpha 1-interferon gene transfer into metastatic Friend leukemia cells abrogated tumorigenicity in immunocompetent mice: antitumor therapy by means of interferon-producing cells, Cancer Res, 53, 1107 Ferrantini, 1994, IFN-alpha 1 gene expression into a metastatic murine adenocarcinoma (TS/A) results in CD8+ T cell-mediated tumor rejection and development of antitumor immunity. Comparative studies with IFN-gamma-producing TS/A cells, J Immunol, 153, 4604, 10.4049/jimmunol.153.10.4604 Belardelli, 1998, The induction of in vivo proliferation of long-lived CD44hi CD8+ T cells after the injection of tumor cells expressing IFN-alpha1 into syngeneic mice, Cancer Res, 58, 5795 Gogas, 2006, Prognostic significance of autoimmunity during treatment of melanoma with interferon, N Engl J Med, 354, 709, 10.1056/NEJMoa053007 Proietti, 2002, Type I IFN as a natural adjuvant for a protective immune response: lessons from the influenza vaccine model, J Immunol, 169, 375, 10.4049/jimmunol.169.1.375 Tough, 2012, Modulation of T-cell function by type I interferon, Immunol Cell Biol, 90, 492, 10.1038/icb.2012.7 Lorenzi, 2011, Type I IFNs control antigen retention and survival of CD8alpha(+) dendritic cells after uptake of tumor apoptotic cells leading to cross-priming, J Immunol, 186, 5142, 10.4049/jimmunol.1004163 Diamond, 2011, Type I interferon is selectively required by dendritic cells for immune rejection of tumors, J Exp Med, 208, 1989, 10.1084/jem.20101158 Fuertes, 2013, Type I interferon response and innate immune sensing of cancer, Trends Immunol, 34, 67, 10.1016/j.it.2012.10.004 Merad, 2013, The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting, Annu Rev Immunol, 31, 563, 10.1146/annurev-immunol-020711-074950 Bracci, 2013, Exploiting dendritic cells in the development of cancer vaccines, Expert Rev Vaccines, 12, 1195, 10.1586/14760584.2013.836905 Parlato, 2001, Expression of CCR-7, MIP-3beta, and Th-1 chemokines in type I IFN-induced monocyte-derived dendritic cells: importance for the rapid acquisition of potent migratory and functional activities, Blood, 98, 3022, 10.1182/blood.V98.10.3022 Santodonato, 2003, Monocyte-derived dendritic cells generated after a short-term culture with IFN-alpha and granulocyte-macrophage colony-stimulating factor stimulate a potent Epstein–Barr virus-specific CD8+ T cell response, J Immunol, 170, 5195, 10.4049/jimmunol.170.10.5195 Lapenta, 2003, Potent immune response against HIV-1 and protection from virus challenge in hu-PBL-SCID mice immunized with inactivated virus-pulsed dendritic cells generated in the presence of IFN-alpha, J Exp Med, 198, 361, 10.1084/jem.20021924 Lapenta, 2006, IFN-alpha-conditioned dendritic cells are highly efficient in inducing cross-priming CD8(+) T cells against exogenous viral antigens, Eur J Immunol, 36, 2046, 10.1002/eji.200535579 Parlato, 2010, LOX-1 as a natural IFN-alpha-mediated signal for apoptotic cell uptake and antigen presentation in dendritic cells, Blood, 115, 1554, 10.1182/blood-2009-07-234468 Santini, 2011, Interferon-alpha-conditioned human monocytes combine a Th1-orienting attitude with the induction of autologous Th17 responses: role of IL-23 and IL-12, PLoS ONE, 6, e17364, 10.1371/journal.pone.0017364 Bracci, 2008, Efficient stimulation of T cell responses by human IFN-alpha-induced dendritic cells does not require Toll-like receptor triggering, J Immunother, 31, 466, 10.1097/CJI.0b013e318174a52a Spadaro, 2012, IFN-alpha enhances cross-presentation in human dendritic cells by modulating antigen survival, endocytic routing, and processing, Blood, 119, 1407, 10.1182/blood-2011-06-363564 Vermi, 2011, Spontaneous regression of highly immunogenic Molluscum contagiosum virus (MCV)-induced skin lesions is associated with plasmacytoid dendritic cells and IFN-DC infiltration, J Investig Dermatol, 131, 426, 10.1038/jid.2010.256 Farkas, 2008, Interferon-alpha and viral triggers promote functional maturation of human monocyte-derived dendritic cells, Br J Dermatol, 158, 921, 10.1111/j.1365-2133.2008.08508.x Di Pucchio, 2006, Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T cells and monocyte/dendritic cell precursors, Cancer Res, 66, 4943, 10.1158/0008-5472.CAN-05-3396 Hawkins, 2009, Vaccination of patients with metastatic renal cancer with modified vaccinia Ankara encoding the tumor antigen 5T4 (TroVax) given alongside interferon-alpha, J Immunother, 32, 424, 10.1097/CJI.0b013e31819d297e Amato, 2009, Vaccination of renal cell cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) alone or administered in combination with interferon-alpha (IFN-alpha): a phase 2 trial, J Immunother, 32, 765, 10.1097/CJI.0b013e3181ace876 Trepiakas, 2010, Vaccination with autologous dendritic cells pulsed with multiple tumor antigens for treatment of patients with malignant melanoma: results from a phase I/II trial, Cytotherapy, 12, 721, 10.3109/14653241003774045 Alfaro, 2011, Pilot clinical trial of type 1 dendritic cells loaded with autologous tumor lysates combined with GM-CSF, pegylated IFN, and cyclophosphamide for metastatic cancer patients, J Immunol, 187, 6130, 10.4049/jimmunol.1102209 Kameshima, 2011, Immunogenic enhancement and clinical effect by type-I interferon of anti-apoptotic protein, survivin-derived peptide vaccine, in advanced colorectal cancer patients, Cancer Sci, 102, 1181, 10.1111/j.1349-7006.2011.01918.x Kawaguchi, 2012, SYT-SSX breakpoint peptide vaccines in patients with synovial sarcoma: a study from the Japanese Musculoskeletal Oncology Group, Cancer Sci, 103, 1625, 10.1111/j.1349-7006.2012.02370.x Kameshima, 2013, Immunotherapeutic benefit of alpha-interferon (IFNalpha) in survivin2B-derived peptide vaccination for advanced pancreatic cancer patients, Cancer Sci, 104, 124, 10.1111/cas.12046 Tanaka, 2013, Potential survival benefit of anti-apoptosis protein: survivin-derived peptide vaccine with and without interferon alpha therapy for patients with advanced or recurrent urothelial cancer – results from phase I clinical trials, Clin Dev Immunol, 2013, 262967, 10.1155/2013/262967 Zeestraten, 2013, Addition of interferon-alpha to the p53-SLP(R) vaccine results in increased production of interferon-gamma in vaccinated colorectal cancer patients: a phase I/II clinical trial, Int J Cancer, 132, 1581, 10.1002/ijc.27819 Rizza, 2008, Evaluation of the effects of human leukocyte IFN-alpha on the immune response to the HBV vaccine in healthy unvaccinated individuals, Vaccine, 26, 1038, 10.1016/j.vaccine.2007.12.044 Launay, 2008, Effect of sublingual administration of interferon-alpha on the immune response to influenza vaccination in institutionalized elderly individuals, Vaccine, 26, 4073, 10.1016/j.vaccine.2008.05.035 Couch, 2009, Contrasting effects of type I interferon as a mucosal adjuvant for influenza vaccine in mice and humans, Vaccine, 27, 5344, 10.1016/j.vaccine.2009.06.084 Miquilena-Colina, 2009, Recombinant interferon-alpha2b improves immune response to hepatitis B vaccination in haemodialysis patients: results of a randomised clinical trial, Vaccine, 27, 5654, 10.1016/j.vaccine.2009.07.014 Nistico, 2009, Chemotherapy enhances vaccine-induced antitumor immunity in melanoma patients, Int J Cancer, 124, 130, 10.1002/ijc.23886 Sun, 1998, Type I interferon-mediated stimulation of T cells by CpG DNA, J Exp Med, 188, 2335, 10.1084/jem.188.12.2335 Dunn, 2005, A critical function for type I interferons in cancer immunoediting, Nat Immunol, 6, 722, 10.1038/ni1213 Kotredes, 2013, Interferons as inducers of apoptosis in malignant cells, J Interferon Cytokine Res: Off J Int Soc Interferon Cytokine Res, 33, 162, 10.1089/jir.2012.0110 Duewell, 2014, RIG-I-like helicases induce immunogenic cell death of pancreatic cancer cells and sensitize tumors toward killing by CD8 T cells, Cell Death Differ, 10.1038/cdd.2014.96 Kroemer, 2013, Immunogenic cell death in cancer therapy, Annu Rev Immunol, 31, 51, 10.1146/annurev-immunol-032712-100008 Fang, 2012, Histone H3 lysine 9 di-methylation as an epigenetic signature of the interferon response, J Exp Med, 209, 661, 10.1084/jem.20112343 Genin, 2012, Recruitment of histone deacetylase 3 to the interferon-A gene promoters attenuates interferon expression, PLoS ONE, 7, e38336, 10.1371/journal.pone.0038336 Hudak, 2012, Low dosed interferon alpha augments the anti-tumor potential of histone deacetylase inhibition on prostate cancer cell growth and invasion, Prostate, 72, 1719, 10.1002/pros.22525 Sugimoto, 2014, Valproic acid enhances the anti-tumor effect of pegylated interferon-alpha towards pancreatic cancer cell lines, Anticancer Res, 34, 3403 Mokyr, 2006, Importance of signaling via the IFN-alpha/beta receptor on host cells for the realization of the therapeutic benefits of cyclophosphamide for mice bearing a large MOPC-315 tumor, Cancer Immunol Immunother, 55, 459, 10.1007/s00262-005-0029-2 Burnette, 2011, The efficacy of radiotherapy relies upon induction of type I interferon-dependent innate and adaptive immunity, Cancer Res, 71, 2488, 10.1158/0008-5472.CAN-10-2820 Sistigu, 2014, Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy, Nat Med, 10.1038/nm.3708